Oligopeptides for Cancer Immunotherapy
Cytotoxic T lymphocytes (CTL) kill tumour cells upon recognition of oligopeptides derived from tumour-associated antigens (TAA). These are presented by major histocompatibility complex (MHC) class I molecules on the surface of the tumour cells. TAA of certain categories differ with respect to their tumour specificity: mutated antigens and so-called “cancer/germ line” (C/G) antigens are considered strictly or highly tumour specific whereas differentiation antigens are expressed in tumours and the tissues the tumours originate from. The expression of C/G antigens was demonstrated in a variety of cancer types.
Further Information: PDF
IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50
Contact
Dr. Klaus Kobek
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Recovering phosphorus from sewage sludge ash
Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…
Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids
EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…
After 25 years, researchers uncover genetic cause of rare neurological disease
Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…
